Baloxavir marboxil: un potente inhibidor de la endonucleasa cap-dependiente de los virus gripales

• Main Authors: Reina, Jordi, Reina, Nuria
• Format: Text
• Language: English
• Published: Sociedad Española de Quimioterapia 2019
• Subjects: Revisión; Avian flu
• Online Access: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6372968/; http://www.ncbi.nlm.nih.gov/pubmed/30676002

Baloxavir marboxil (5-hydroxy-4-pyridone-3-carboxyl acid) is a new antiviral drug with special efficacy on influenza viruses that acts by inhibiting the cap-dependent endonuclease required for its replication. It is the first representative of the so-called inhibitors of influenza-like PB2. It has shown efficacy against influenza viruses A and B and most strains of animal origin (avian flu). Clinical trials conducted in healthy patients between 12 and 64 years without pathologies and not hospitalized (mild flu) have shown a reduction in the duration of symptoms similar to that obtained by oseltamivir. However, baloxavir is a much more potent inhibitor of viral replication than this drug. It has been shown as a safe and well tolerated drug. A single dose of 40-80 mg is administered the first 48 hours after onset of symptoms. In these trials, strains with moderate sensitivity (PA / I38T mutants) were detected in 2.2% of influenza A (H1N1) pdm09 and in 9.7% of influenza A (H3N2). Although these data could be a good drug to treat mild or moderate influenza, requiring trials in severe influenza and patients with chronic diseases to establish their true clinical utility.